Praxis Precision Medicines Inc - Asset Resilience Ratio
Praxis Precision Medicines Inc (PRAX) has an Asset Resilience Ratio of 20.42% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Praxis Precision Medicines Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Praxis Precision Medicines Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PRAX total asset value.
Liquid Assets Composition Over Time
This chart breaks down Praxis Precision Medicines Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Praxis Precision Medicines Inc (PRAX) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $283.79 Million | 20.42% |
| Total Liquid Assets | $283.79 Million | 20.42% |
Asset Resilience Insights
- Good Liquidity Position: Praxis Precision Medicines Inc maintains a healthy 20.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Praxis Precision Medicines Inc Industry Peers by Asset Resilience Ratio
Compare Praxis Precision Medicines Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Praxis Precision Medicines Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Praxis Precision Medicines Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.80% | $242.00 Million | $937.91 Million | -10.88pp |
| 2024-12-31 | 36.68% | $177.19 Million | $483.11 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $87.95 Million | -- |
| 2022-12-31 | 33.77% | $38.87 Million | $115.13 Million | -13.10pp |
| 2021-12-31 | 46.87% | $137.21 Million | $292.75 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $303.18 Million | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more